Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that new preclinical data ...
Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead program CBX-250.
Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results